At the 33rd European Congress on Obesity (ECO 2026) in Istanbul, Türkiye, the global pharmaceutical community received a pivotal update regarding the next generation of weight-management therapies. Novo Nordisk presented the long-awaited findings from its Phase 3a REDEFINE-1 trial, casting a spotlight on the fixed-dose combination of cagrilintide and semaglutide, known as CagriSema.
As the medical field grapples with the long-term implications of rapid pharmacological weight loss, the primary concern has shifted from simply "how much weight is lost" to "what kind of weight is lost." The findings presented by Dr. Eric Ravussin suggest that CagriSema not only facilitates profound body mass reduction but does so while preserving physical function and optimizing body composition.
The Challenge of Muscle Loss in Modern Pharmacotherapy
The emergence of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has revolutionized the treatment of obesity. However, clinical researchers have long recognized a "muscle-loss paradox." As patients shed significant amounts of adipose tissue, they often experience a concomitant reduction in lean soft tissue (LST). This creates a clinical risk for sarcopenia—a condition characterized by the loss of muscle mass and strength—which can ironically diminish the physical functionality that weight loss is intended to improve.
The REDEFINE-1 trial (NCT05567796) was explicitly designed to look beneath the surface of the scale. By utilizing dual-energy X-ray absorptiometry (DXA) and functional testing, the study sought to determine if the potent weight-loss efficacy of CagriSema could be achieved without compromising the structural integrity of the patient’s musculature.
Chronology of the REDEFINE-1 Trial
The trial was structured as a rigorous 68-week, randomized, double-blind, placebo- and active-controlled, multicenter investigation. The scope of the study underscored the high stakes of the research:
- Participant Enrollment: A total of 3,417 participants, all meeting the clinical definition of obesity (BMI ≥30kg/m² or ≥27 kg/m² with at least one obesity-related complication), were enrolled.
- Study Arms: Participants were randomized in a 21:3:3:7 ratio into four groups: CagriSema (2.4mg/2.4mg), semaglutide (2.4mg), cagrilintide (2.4mg), or a placebo. All treatments were administered as once-weekly subcutaneous injections alongside a standardized reduced-calorie diet and increased physical activity regimen.
- Mid-Trial Assessments: Muscle strength was assessed via the Sit-to-Stand (STS) test, a reliable marker for lower-body physical performance.
- The DXA Subgroup: A specialized cohort of 1,038 participants underwent rigorous testing, with 252 participants undergoing comprehensive DXA scans to map changes in bone density, fat mass, and lean soft tissue.
- The Data Reveal: At the May 2026 congress, the final analysis was presented, confirming the efficacy of the dual-mechanism approach.
Supporting Data: Fat Reduction and Muscle Preservation
The data presented by Dr. Eric Ravussin, Director of the Human Translational Physiology Laboratory at the Pennington Biomedical Research Center, provided a granular look at how weight is distributed during the treatment period.
Efficacy of Weight Loss
CagriSema 2.4mg/2.4mg emerged as the most potent intervention in the study, achieving a staggering 23.9% reduction in total body weight at week 68. In comparison, the monotherapy arms showed significant but lower efficacy: semaglutide reached 16.6% reduction, while cagrilintide reached 15.0%. The placebo group saw a modest 2.8% reduction.
Body Composition Analysis
The most encouraging aspect of the findings was the "quality" of the weight lost.
- Fat Mass Dominance: In the CagriSema group, 66.9% of the total weight loss was attributed to the reduction of fat mass.
- Relative Lean Tissue Improvement: While an absolute reduction in LST is inevitable during rapid weight loss, the study noted a significant shift in body composition. In patients who achieved ≥30% body weight loss, the proportion of fat mass plummeted from 46.3% to 33.2%, while the proportion of lean soft tissue actually increased from 51.3% to 63.2%.
- Functional Integrity: Crucially, the STS test confirmed that muscle strength did not decline relative to the placebo group. This indicates that while the body becomes lighter, it does not become weaker, effectively mitigating concerns about sarcopenia.
Implications for Patient-Reported Outcomes
Physical health is often measured by what a patient can do, not just what the scale says. The REDEFINE-1 study integrated the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQoL-Lite-CT) and the SF-36v2 Health Survey.
The results were decisive: CagriSema-treated patients reported significant improvements in their physical function scores compared to the placebo arm. This correlation between improved body composition—a higher ratio of lean-to-fat mass—and enhanced quality of life metrics provides a strong justification for the long-term use of the drug in clinical practice.
Competitive Landscape and Market Outlook
The pharmaceutical industry is currently witnessing an "arms race" in metabolic health. With the obesity market expanding rapidly, CagriSema is positioned to be a flagship offering for Novo Nordisk.
Reshaping the Market
Key opinion leaders (KOLs) within the endocrine and metabolic sectors have noted that CagriSema’s performance aligns with, and in some areas may exceed, the efficacy of current heavy hitters like tirzepatide. By combining a long-acting amylin analogue (cagrilintide) with a GLP-1RA (semaglutide), the drug creates a "dual-mechanism" synergy that addresses both satiety and metabolic efficiency.
Future Development Pipelines
According to the GlobalData Pharma Intelligence Center, the landscape is incredibly crowded, with:
- 48 Phase III candidates
- 112 Phase II candidates
- 158 Phase I candidates
Despite this saturation, the specific focus on "muscle preservation" in the REDEFINE-1 trial provides a unique selling proposition for CagriSema. As healthcare providers look for treatments that address the healthspan of the patient—not just the BMI number—drugs that can demonstrate functional physical preservation will likely command a premium in the market.
Conclusion: The Path Forward
The findings from the 33rd European Congress on Obesity represent a maturing of the obesity treatment field. The era of focusing exclusively on weight loss is giving way to a more sophisticated era of body composition management.
CagriSema appears to be a major step forward, effectively balancing the need for significant adipose reduction with the necessity of maintaining metabolic and physical health. As the drug moves through the final stages of pre-registration in the United States and global regulatory reviews, the clinical community remains optimistic. If these results translate to real-world clinical settings, CagriSema will not only help patients lose weight—it will help them maintain the strength necessary to live active, healthier lives.
For the millions of individuals struggling with obesity and its associated complications, the data from Istanbul offers a promising glimpse of a future where medical intervention provides holistic health restoration rather than just a lower number on the scale.
